CCHR Calls FDA Approval of Psychotropics & Electroshock a Colossal Conflict of Interest
Press release content from Globe Newswire. The AP news staff was not involved in its creation. CLEARWATER, Fla., March 06, 2019 (GLOBE NEWSWIRE) — The Food and Drug Administration (FDA) is considering approving Johnson & Johnson’s (J&Js) new nasal spray antidepressant, esketamine (brand name Spravato), after an FDA advisory committee voted on February 12, 2019 in its favor. The drug...
READ MORE CCHR Calls FDA Approval of Psychotropics & Electroshock a Colossal Conflict of Interest